[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatobiliary-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatobiliary-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,70,119,156,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100536139","targeted-navigation-in-hepatocellular-carcinoma-hcc-100536139",false,"NCT06260943","Targeted Navigation in Hepatocellular Carcinoma (HCC)","Targeted Navigation to Achieve Health Equity: Increasing Access to Care, Patient Engagement and Research Participation","Inclusion Criteria:\n\n* HCC Patients:\n\n  * Enrolled or eligible for enrollment in Unified Prospective Registry and Biorepository of Patients with Chronic Liver Disease or Hepatobiliary Cancers Including Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma.\n  * Diagnosis of hepatocellular carcinoma, confirmed by clinical chart review and International Classification of Diseases, Tenth Revision (ICD-10) C22.0.\n  * Adults, age 18 or older\n  * Able to provide informed consent\n* All other interviewees:\n\n  * Advocates who will self-identify as having had HCC.\n  * Others who self-identify as either a caregiver or support person of an HCC patient.\n\nPhysicians\u002FLicensed Independent Practitioners, Social Workers, Nurse Navigators, and Research Coordinators will all self-identify as being involved in the care of HCC patients.\n\nExclusion Criteria:\n\n* Unable to speak Spanish or English\n* West Haven Grade 2 or higher hepatic encephalopathy19 or other cognitive impairment.\n* Adults unable or unwilling to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* Given that this study is minimal risk and there are no risks to a potential fetus, investigators will not exclude pregnant women; however, no data about pregnancy or their fetus is being collected",true,"ALL","18 Years",{"count":20,"type":21},210,"ESTIMATED","INTERVENTIONAL",[24],"NA","The investigators are trying to learn more about the personal perceptions and experiences regarding the needs of patients with liver cancer to help improve the care of all patients. The investigators would like to know whether there are needs that patients have or are aware of, especially those needs that the investigators have not been able to address. The investigators aim to develop a program that helps participants and participant's families to navigate the process of being diagnosed with liver cancer and receiving treatment.",[27,28,29],"Hepatocellular Carcinoma","Cholangiocarcinoma","Hepatobiliary Cancer","RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":34},"2024-04-15",{"date":38,"type":21},"2026-10-31",{"name":40,"class":41},"University of Miami","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100477481","pilot-comparing-ctdna-idv-vs-spv-sample-in-pts-undergoing-biopsies-for-hepatobiliary-and-pancreatic-cancers-100477481","NCT05497531","Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers","Pilot Trial Comparing Circulating Tumor DNA (ctDNA) From Immediate Draining Vein vs. Standard Peripheral Vein Sample in Patients Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers","Inclusion Criteria:\n\n* 18 years of age or older\n* Have or are undergoing work-up for hepatobiliary and\u002For pancreatic carcinoma (such as hepatocellular carcinoma, cholangiocarcinoma, ampullary carcinoma, pancreatic carcinoma)\n* Scheduled for an image-guided percutaneous or trans-jugular biopsy of a lesion\n* Must be able to provide a written informed consent\n\nExclusion Criteria:\n\n* Patients unable to hold reasonably still on a procedure table or hold their breath during imaging or needle passes\n* Patients with a gross body weight over 375 pounds (upper limit of the CT and angiography tables)\n* Patients with uncorrectable coagulopathy\n* Platelet count \\\u003C 30,000\u002Ful\n* International Normalized (INR) \\> 1.5\n* Patients with moderate to severe ascites who cannot undergo trans-jugular biopsy or sufficient drainage\n* No clear reachable target for percutaneous or trans-jugular biopsy\n* Patient who cannot have a peripheral blood draw for ctDNA",{"count":51,"type":21},15,[24],"This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies for hepatobiliary and pancreatic cancers.",[29,55,27,28,56,57],"Pancreatic Cancer","Ampullary Cancer","Pancreatic Carcinoma",[59,60,55,29],"ctDNA","Circulating Tumor DNA","2026-02-23",{"date":63,"type":34},"2026-02-24",{"date":65,"type":34},"2022-09-07",{"date":67,"type":21},"2026-06",{"name":69,"class":41},"University of California, Irvine",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":16,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":102,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":118},"100467447","cfdna-assay-prospective-observational-validation-for-early-cancer-detection-and-minimal-residual-disease-100467447","NCT05366881","cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease","cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse","CAMPERR","Case Inclusion Criteria:\n\n* Newly diagnosed (within 120 days) with cancer or a recurrence of a cancer diagnosed \\>5 years ago of one of the following subtypes: Invasive Brain, Breast, Bladder, Cervical, Colorectal, Endometrial, Esophageal, Gastric, Head and Neck, Hepatobiliary, Lung, Ovarian, Pancreatic, Prostate, Renal, Sarcoma, Thyroid; Leukemia, Lymphoma, Multiple Myeloma\n* Able and willing to provide informed consent\n* ≥40 years of age\n\nCase Exclusion Criteria:\n\n* Currently receiving any treatment for cancer\n* Currently taking any demethylating agents\u002FDNA hypomethylating agents\n* Simultaneously diagnosed with two or more invasive cancers\n* Diagnosed with any invasive or non-invasive cancer in addition to the index cancer in the last 5 years\n* Currently diagnosed with any chronic hematopoietic cancer (e.g. chronic CLL) in addition to the index cancer\n* Currently diagnosed with any myelodysplastic syndromes and\u002For precursor hematologic conditions (e.g. MGUS) in addition to the index cancer\n* Women who are known to be pregnant (self-reported)\n\nControl Inclusion Criteria\n\n* Not diagnosed with any cancer in the last 5 years (non-invasive cancer is allowed)\n* Able and willing to provide informed consent\n* ≥40 years of age\n\nControl Exclusion Criteria\n\n* Currently receiving any treatment for cancer\n* Currently taking any demethylating agents\u002FDNA hypomethylating agents\n* Women who are known to be pregnant (self-reported)","40 Years",{"count":80,"type":21},7000,"OBSERVATIONAL","This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care.\n\nAdditionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in lung cancer. This cancer was selected based on the existing clinical landscape and treatment availability.",[84,85,86,87,88,89,90,91,92,29,93,94,95,96,97,55,98,99,100,101],"Brain Cancer","Breast Cancer","Bladder Cancer","Cervical Cancer","Colorectal Cancer","Endometrial Cancer","Esophageal Cancer","Stomach Cancer","Head and Neck Cancer","Leukemia","Lung Cancer","Lymphoma","Multiple Myeloma","Ovarian Cancer","Prostate Cancer","Renal Cancer","Sarcoma","Thyroid Cancer",[103,104,105,106,107],"Multi-cancer early detection","Liquid Biopsy","Methylome","Cancer screening","cell-free DNA","2026-01-16",{"date":110,"type":34},"2026-01-20",{"date":112,"type":34},"2022-05-03",{"date":114,"type":21},"2027-03",{"name":116,"class":117},"Adela, Inc","INDUSTRY",17,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":127,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100592905","phase-2-impact-of-comprehensive-geriatric-management-on-morbidity-and-quality-of-life-in-elderly-patients-undergoing-major-hepatectomy-and-pancreaticoduodenectomy-for-cancer-100592905","NCT06999512","Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer","Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer. A Randomized Controlled Trial.","HPB70+","Inclusion Criteria:\n\n* Patients ≥ 70 years, with histologically proven or clinical diagnosis of HPB cancer among the following:\n* hepatocellular carcinoma\n* intra-hepatic and peri-hilar cholangiocarcinoma\n* gallbladder cancer\n* peri-ampullary malignant tumors\n* pancreatic adenocarcinoma\n* colorectal liver metastases\n* Needing one of the following procedures:\n* Pancreaticoduodenectomy\n* Major Hepatectomy (≥ 3 hepatic segments)\n\nExclusion Criteria:\n\n* Patients who have no access to the French health system.\n* Patient unable to sign informed consent.\n* Patients included in a double-blind randomized trial\n* Patients legally protected","70 Years",{"count":129,"type":21},526,[131,132],"PHASE2","PHASE3","The worldwide incidence of hepatobiliary and pancreatic (HPB) cancers is dramatically increasing especially for pancreatic cancer. Increasing age is associated with increased cancer risk. In North America and Europe, most people who are diagnosed with cancer every year are aged 65 years or older. Hepatectomy for hepatocellular carcinoma, intra hepatic and hilar cholangiocarcinoma, gallbladder cancer and hepatic metastases from colorectal cancer allows better survival compared to other treatments. Similarly, pancreaticoduodenectomy (PD) is the standard of care in patients with distal cholangiocarcinoma and patients with resectable pancreatic adenocarcinoma located in the head of the pancreas. This results in an increasing number of elderly patients being evaluated for hepatic and pancreatic surgery. Major hepatectomy and PD are amongst the most invasive and complex procedures in general surgery with high rates of morbidity as well as negative impact on quality of life. Many studies have reported poor post-surgical outcomes in the elderly patients, especially related to co-morbidities that characterizes this population such as, polypharmacy, cognitive decline, depression and malnutrition. The age in elderly cancer patient is not just a number. The management of these patients should not be limited to oncological care, but it should be extended to different clinical domains including physical, cognitive, psychological, socioeconomic and environmental aspects. In this population, the risk of adverse postoperative outcomes is not adequately described by routine format of current preoperative evaluation, such as age, comorbidities and other traditional tests. Furthermore, the Comprehensive Geriatric Assessment (CGA) is scarcely considered. The aim of CGA is to identify current health problems and to guide interventions thus reducing adverse outcomes and optimizing the functional status of older adults. Several trials have indeed shown that CGA and perioperative tailored interventions reduce morbidity and improve patient survival in other surgical disciplines. Similar data is lacking in both hepatic and pancreatic surgery.\n\nThe hypothesis is that CGA with perioperative tailored interventions could reduce postoperative morbidity in elderly patients after major hepatectomy and pancreaticoduodenectomy for cancer.",[29,55],[136,137,138,139,140,141,142,143,144],"patient over 70 years","hepatocellular carcinoma","intra-hepatic and peri-hilar cholangiocarcinoma","gallbladder cancer","peri-ampullary malignant tumors","pancreatic adenocarcinoma","colorectal liver metastases","Major Hepatectomy","Pancreaticoduodenectomy","NOT_YET_RECRUITING","2025-05-30",{"date":148,"type":34},"2025-05-31",{"date":150,"type":21},"2025-09",{"date":152,"type":21},"2030-12",{"name":154,"class":41},"Assistance Publique - Hôpitaux de Paris",12,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":176,"locationsCount":178},"100576126","genotype-phenotype-relationship-between-cryptogenic-cholestasis-and-familial-intrahepatic-cholestasis-100576126","NCT06781242","Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis","Genotype-phenotype Relationship Between Adult Cryptogenic Cholestasis and Mutations in Genes Responsible for Progressive Familial Intrahepatic Cholestasis","Inclusion Criteria:\n\n* age ≥ 18 years\n* diagnosis of PFIC\u002FCCLDs\u002FHBCs\n* obtaining informed consent\n\nExclusion Criteria:\n\n* Another documented cause of chronic liver disease capable of justifying the clinical phenotype",{"count":164,"type":21},300,"Genotype-phenotype relationship between adult cryptogenic cholestasis and mutations in genes responsible for progressive familial intrahepatic cholestasis",[167,168,169,29],"Cholestatic Liver Disease","Intrahepatic Cholestasis","Progressive Familial Intrahepatic Cholestasis","2025-01-13",{"date":172,"type":34},"2025-01-17",{"date":174,"type":34},"2024-01-16",{"date":150,"type":21},{"name":177,"class":41},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",2,{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":200,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":214},"100400786","stereotactic-body-radiotherapy-in-patients-with-rare-oligometastatic-cancers-oligorare-100400786","NCT04498767","Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)","Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial","OligoRARE","Inclusion Criteria:\n\n* Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.\n* Controlled primary tumour, defined as:\n* at least 3 months since original tumour treated definitively, with no progression at primary site\n* Total number of oligometastases of 1-5 including:\n* Brain metastases amenable to radiosurgery or fractionated stereotactic radiotherapy patient who had neurosurgical resection before trial inclusion are allowed and resected brain metastases count to the total number of oligometastases\n* All sites of disease can be safely treated based on the judgement of an experienced radiation oncologist\n* ECOG score 0-2\n* Life expectancy \\> 6 months\n* Age 18 or older\n* Before patient randomization, written informed consent must be given according to ICH\u002FGCP, and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Primary cancer of prostate, breast, lung or colorectal\n* Serious medical comorbidities precluding radiotherapy:\n* These include interstitial lung disease in patients requiring thoracic radiation, Crohn's disease in patients where the GI tract will receive radiotherapy, or ulcerative colitis where the bowel will receive radiotherapy and connective tissue disorders such as lupus or scleroderma.\n* For patients with liver metastases, moderate\u002Fsevere liver dysfunction (Child Pugh B or C)\n* Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein. For patients treated previously with radiation, biological effective dose calculations should be used to equate previous doses to the tolerance doses listed in the RTQA Guidelines. All such cases should be discussed with one of the study coordinators\n* Brain metastases only, without extra-cerebral metastases\n* Malignant pleural effusion, malignant ascites, meningeal carcinomatosis and peritoneal carcinomatosis\n* Maximum size of 6 cm for lesions outside the brain, except:\n* Bone metastases over 5 cm may be included, if in the opinion of the local radiation oncologist it can be treated safely (e.g. rib, scapula, pelvis)\n* Clinical or radiologic evidence of symptomatic spinal cord compression. Patients can be eligible if surgical resection has been performed, but the surgical site counts toward the total of up to 3 metastases.\n* Metastatic disease that invades any of the following: GI tract (including oesophagus, stomach, small or large bowel), mesenteric lymph nodes, or disseminated skin metastases and lymphangiosis\n* Pregnant or breast feeding women\n* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial",{"count":188,"type":21},200,[24],"This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers.\n\nPatients will be randomized in a 1:1 ratio between current standard of care treatment vs. standard of care treatment + SBRT to all sites of known metastatic disease.\n\nThe primary objective of this trial is to assess if the addition of stereotactic body radiotherapy (SBRT) to standard of care treatment improves overall survival (OS) as compared to standard of care treatment alone in patients with rare oligometastatic cancers.",[192,193,92,100,99,86,194,55,29,195,196,90,197,198,199],"Gynecologic Cancer","Skin Cancer","Upper Urinary Tract Carcinoma","Gastric Cancer","Small Bowel Cancer","Melanoma","Colon Cancer","Oligometastasis",[201,202,203],"oligometastatic cancer","Stereotactic body radiotherapy","SBRT","2024-08-23",{"date":206,"type":34},"2024-08-26",{"date":208,"type":34},"2021-06-10",{"date":210,"type":21},"2030-02-01",{"name":212,"class":213},"European Organisation for Research and Treatment of Cancer - EORTC","NETWORK",13]